Key takeaways:
The Findings:
Prevention, Intervention, and Treatment
Background: Researchers from Stanford University analyzed data from more than 282,500 adults in Wales, taking advantage of a unique natural experiment. When Wales launched its shingles vaccination program, people who turned 80 just after the program started were eligible for the vaccine, while those who turned 80 just before the program started remained ineligible for life. This created two groups that were virtually identical in every measurable way (education, health behaviors, prevalence of chronic conditions) except for access to the vaccine.
The results were striking across three stages of the dementia disease course:
Prevention: Among older adults without cognitive impairment, those who received the shingles vaccine had a 20% lower risk of developing dementia over the next seven years compared to those who didn't receive it. That translates to a 3.5 percentage point reduction in dementia diagnoses.
Early intervention: Among those without prior cognitive impairment, vaccinated individuals saw a 3.1 percentage point reduction in mild cognitive impairment (MCI) diagnoses over nine years. MCI is often a precursor to dementia, so reducing MCI diagnoses is clinically significant.
Therapeutic benefit: Perhaps most surprising, among people already living with dementia at the start of the vaccination program, those who received the vaccine had a 29.5 percentage point reduction in deaths due to dementia over nine years. Nearly half of the unvaccinated group with dementia died from the disease during follow-up, compared to only about 30% of the vaccinated group.
The protective effect was significantly stronger in women than in men, though the reasons for this difference aren't yet fully understood.
The Science:
Why the Varicella-Zoster Virus Matters
The varicella-zoster virus causes chickenpox, typically in childhood. After the initial infection resolves, the virus doesn't leave your body. It stays dormant in nerve cells for life. In people who are older or have weakened immune systems, the virus can reactivate decades later to cause shingles, a painful rash characterized by blisters.
But the virus's impact may extend beyond the rash. Research has linked varicella-zoster to several mechanisms that contribute to Alzheimer's disease and other dementias:
Amyloid deposition and tau aggregation: The virus has been linked to the formation of amyloid plaques and tau tangles, the hallmark pathological features of Alzheimer's disease.
Cerebrovascular disease: Varicella-zoster is associated with patterns of blood vessel damage in the brain that resemble those seen in Alzheimer's disease, including small and large vessel disease, ischemia, infarction, and hemorrhage.
Neuroinflammation: Clinical and subclinical reactivations of the virus create chronic immune stress that drives inflammatory pathways in both the peripheral and central nervous systems, interfering with healthy brain aging.
HSV-1 reactivation: Some evidence suggests that varicella-zoster reactivations may trigger reactivations of herpes simplex virus (HSV-1) in the brain, which has also been linked to dementia development.
By preventing these viral reactivations, the shingles vaccine may interrupt multiple pathways that contribute to cognitive decline.
What This Means:
An Accessible Intervention
Bottom Line: What makes this research particularly exciting is how actionable it is. The shingles vaccine isn't an experimental treatment years away from approval. Shingrix, the recombinant shingles vaccine, is already widely available and recommended for all adults 50 and older. It's more than 90% effective at preventing shingles and has a strong safety record.
Most insurance plans, including Medicare, cover the vaccine. It's administered as two doses, typically given two to six months apart.
This study's natural experiment design provides some of the strongest evidence to date for a causal relationship between the vaccine and reduced dementia risk. Because the two comparison groups were so similar in every measurable way except for vaccine eligibility, bias is much less likely than in typical observational studies. The research team has now replicated these findings in health records from Australia, Canada, England, and New Zealand.
"We just keep seeing this strong protective signal for dementia in dataset after dataset," said Dr. Pascal Geldsetzer, senior author of the study.
The dual benefit (preventing a painful, debilitating condition while also reducing dementia risk) makes this one of the more interesting preventive interventions currently available.
If you're 50 or older and haven't received the Shingrix vaccine, talk to your doctor about whether it's appropriate for you. Check your vaccination status and confirm whether your insurance covers it (most plans do).
This is particularly relevant for women, who showed stronger protective effects in the research. Even if you have mild cognitive impairment or early-stage dementia, the study suggests potential benefits across the disease course, making it worth discussing with your healthcare provider.
The shingles vaccine illustrates a broader principle that's central to BetterBrain's approach: reducing systemic inflammation protects your brain. The pathways through which varicella-zoster contributes to dementia (chronic inflammation, vascular damage, protein aggregation) are some of the same pathways affected by the health domains we assess.
And if you haven't yet, join BetterBrain today and take the first step on your brain health journey.
.webp)